Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase 1/2 2Phase NA 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Head & Neck 2Gynecologic 2Genitourinary 2Dermatologic 2Lymphoid 1Breast 1

Conditions

Ovarian Neoplasms 325Uterine Cervical Neoplasms 131Endometrial Neoplasms 109Breast Neoplasms 99Carcinoma, Non-Small-Cell Lung 85Fallopian Tube Neoplasms 77Colorectal Neoplasms 74Carcinoma, Ovarian Epithelial 71Neoplasms 63Pancreatic Neoplasms 62Stomach Neoplasms 59Melanoma 57Neoplasm Metastasis 51Triple Negative Breast Neoplasms 49Squamous Cell Carcinoma of Head and Neck 43Prostatic Neoplasms 42Lung Neoplasms 41Esophageal Neoplasms 40Head and Neck Neoplasms 39Urinary Bladder Neoplasms 32Carcinoma, Renal Cell 31Sarcoma 29Recurrence 28Small Cell Lung Carcinoma 26Colonic Neoplasms 25Carcinoma, Hepatocellular 24Carcinoma, Transitional Cell 20Uterine Neoplasms 16Peritoneal Neoplasms 15Mesothelioma 15

Interventions

pembrolizumab 1epacadostat 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Microsatellite Instability × Gynecologic × Clear all
NCT05592626 2025-07-09

START-001

Marengo Therapeutics, Inc.

Phase 1/2 Recruiting
365 enrolled
DermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Abdominal Neoplasms, Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Carcinoma, Basal Cell, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Genital Neoplasms, Female, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Site, Stomach Neoplasms, Urogenital Neoplasms, Vulvar Diseases, Vulvar Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Epstein-Barr Virus Infections, Papillomavirus Infections, Microsatellite Instability, Small Cell Lung Carcinoma

NCT02178722 2022-02-14

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Incyte Corporation

Phase 1/2 Completed
444 enrolled 19 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Microsatellite Instability, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡